
OUR FOCUS
Committed to Successful Outcomes
One of the Healthcare industry’s most active subsectors, Biopharma draws strong corporate and investor interest in the development of novel medicines to treat significant unmet medical needs. Having a reliable, ongoing source of capital is key to funding the lengthy process of bringing therapies to market.
Investors and corporate clients repeatedly turn to Leerink Partners’ experience and expertise to unlock the growth potential of innovative biopharma companies.
Recent transactions

$60 Million
Sole Agent
At-the-Market Facility
May 2025

$75 Million
Joint Bookrunner
Follow-On
May 2025

$125 Million
Exclusive Financial Advisor
Venture Debt Facility
May 2025

$250 Million
Exclusive Financial Advisor
Term Loan Facility
May 2025